29 November 2023
Benchmark Holdings plc
("Benchmark" or the "Company")
Directorate Change
The Company is pleased to announce the appointment of Jonathan Esfandi as Non-Executive Director. Mr Esfandi is the founder and managing partner at JNE Partners LLP.
Mr. Esfandi will act as shareholder representative of JNE Partners LLP, a significant shareholder of the Company, and therefore the Board has concluded that he is not an independent director.
Laura Lavers, who joined the Board in November 2022, will retire from the Board as a Non-Executive Director with effect from today.
Peter George, Chairman, commented:
"We welcome Jonathan to the Board and look forward to working together. On behalf of the Board, I wish to thank Laura Lavers for her contribution over the past year."
The following information is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies in connection with the appointment of Jonathan to the Board of the Company:
Full Name: Jonathan Esfandi
Age: 49
Current Directorships:
JNE PARTNERS LLP
JNE PARTNERS (UK) SERVICES LTD
Former Directorships (previous five years): None within the past five years
Beneficial interest in the equity securities of Benchmark Holdings plc: No direct beneficial interest. Funds managed by JNE Partners LLP have a holding of 169,263,811 shares in Benchmark
There is no further information required to be disclosed under Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.
Enquiries
| |
About Benchmark
Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.
We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.
Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
